New drug combo targets brain to soothe stubborn reflux

NCT ID NCT06945237

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether adding a gut-brain neuromodulator (Flupentixol-Melitracen) to standard acid-reducing therapy (Lansoprazole) helps people with gastroesophageal reflux disease (GERD) who still have symptoms on acid suppressants alone. The trial enrolled 164 adults with GERD and measured symptom improvement using a standard questionnaire. The goal is to see if targeting brain-gut connections can provide better relief for this common condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Flupentixol-Melitracen (a combination drug that affects brain chemicals) plus Lansoprazole (a standard acid-reducing drug)
What this could lead to
If successful, this could offer a new treatment option for GERD patients whose symptoms persist despite standard acid-reducing therapy, potentially improving quality of life.
What could go wrong
This is a small, completed trial with 164 participants, so results may not apply to everyone. The drug combination may cause side effects like drowsiness or allergic reactions, and the benefit over standard care may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL REFLUX DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Shanghai Jiaotong university,renji hospital

    Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.